

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) **December 4, 2013**

REPRO-MED SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

New York
(State or other jurisdiction
of incorporation)

0-12305
(Commission
File Number)

13-3044880
(IRS Employer
Identification No.)

24 Carpenter Road, Chester, New York
(Address of principal executive offices)

10918
(Zip Code)

Registrant's telephone number, including area code **(845) 469-2042**

not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Repro-Med Systems, Inc. announces the resignation of Remo Spagnoli as a director. Mr. Spagnoli, who has served as a member of the Board of Directors since 1993, stated he has enjoyed participating in the Company's growth and success and that the time has come to pass the baton to the next generation. Brad A. Sealfon, age 26, the son of Andrew Sealfon, the Company's President and CEO, and an employee of the Company since 2011, has been elected as a Director.

A copy of Mr. Spagnoli's letter of resignation is annexed hereto as Exhibit 17.1.

Item 8.01 Other Events.

Repro-Med Systems, Inc. announces the Board of Directors has approved a stock buy-back program. The Company's stock trades over-the-counter under the symbol REPR. Following the procedure set forth under SEC Rule 10b-18, the company intends to purchase up to 1,000,000 shares of its stock on the open market when conditions permit.

A copy of the press release is annexed hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

Exhibit 17.1 [Letter of Resignation](#)

Exhibit 99.1 [Press Release](#)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REPRO-MED SYSTEMS, INC.
(Registrant)

Date: December 6, 2013

By: /s/ Andrew I. Sealfon
Andrew I. Sealfon
President and Chief Executive Officer



November 8, 2013

Remo Spagnoli
55 W Searsville Rd.
Montgomery, New York, 12549

Att: RMS Board of Directors:

As you know I have been a supporter of RMS for many years and have really enjoyed participating in the company's growth. The time has come, however, for me to pass the baton to the next generation. It is with regret, therefore, that I am resigning from the RMS board of directors as of the current date.

Please feel free to call on me from time to time if there is anything I can contribute. I wish you all continued growth and success, and you can be sure that I will be following all of your achievements with great interest.

Sincerely,

Handwritten signature of Remo Spagnoli.

Remo Spagnoli

Exhibit 99.1

REPRO-MED ANNOUNCES BOARD CHANGES,
STOCK BUY-BACK PLAN

(Chester, NY – December 4, 2013) --- Repro-Med Systems, Inc., (OTCBB: REPR) d/b/a RMS Medical Products, has announced the resignation from its Board of Directors of Remo (Raymond) Spagnoli. Mr. Spagnoli had served as a director of the Company since 1993.

Mr. Spagnoli stated in his letter of resignation, “I have been a supporter of RMS for many years and have really enjoyed participating in the company’s growth. The time has come, however, for me to pass the baton to the next generation.”

Andrew Sealfon, President and CEO, praised Mr. Spagnoli’s contribution to the company and stated his participation will be missed. Brad A. Sealfon, age 26, Andrew’s son and a full-time employee of the Company since 2011, has been elected as a Director.

At the same time, it was announced that the Board of Directors has approved a stock buy-back program. The Company’s stock trades over-the-counter under the symbol REPR. Following the procedure set forth under SEC Rule 10b-18, the company intends to purchase up to 1,000,000 shares of its stock on the open market when conditions permit.

Andrew Sealfon also reported that the Company is putting renewed focus and resources into an unprecedented generation of product offerings. “Volatility and restrictions on costs in the healthcare market mean RMS must be the highest-value producer in our field, if we are to thrive. We achieve this through a long-held belief, that a well-considered product is one that solves a customer’s most pressing problem, with a superior result and at a lower cost. The best way to provide true company growth and stockholder value is to develop such products with the best interests of our patients foremost on our minds, followed closely by the best interests of our customers, employees and shareholders,” he said.

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “will,” or “plans” to be uncertain and forward looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the company’s reports and registration statements filed with the Securities and Exchange Commission.

For further information:

Mike King

Princeton Research, Inc

(702) 650-3000

Email: mike@princetonresearch.com
